NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. The financial performance shows a significant reduction in net loss, which is positive, but rising operational costs and reliance on cash resources pose concerns. The Q&A section reveals uncertainties in regulatory approval processes and supply chain issues, but the company's strategic initiatives and FDA engagement offer some optimism. Overall, the sentiment is neutral, as positive and negative factors balance each other out.
Key Financial Performance
Net Loss $1.4 million for Q1 2026, a 74% reduction year-over-year from $5.5 million in Q1 2025. This change is primarily related to the impact of certain fair value accounting measures and other nonrecurring charges.
Loss from Operations $4.7 million for Q1 2026, compared to $3.8 million in Q1 2025. The increase is primarily driven by costs related to several targeted strategic initiatives advanced during the quarter.
Research and Development Expense $1.3 million for Q1 2026, compared to $0.8 million in Q1 2025. The increase is primarily driven by costs related to execution towards several targeted strategic initiatives.
General and Administrative Expense $3.8 million for Q1 2026, compared to $2.9 million in Q1 2025. The increase is primarily driven by costs related to execution towards several targeted strategic initiatives.
Cash and Cash Equivalents $6.7 million as of March 31, 2026. Subsequent to the quarter, the company generated approximately $7 million in gross proceeds from its at-the-market facility through the sale of common stock.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KETAFREE: Progressed through FDA review with bioequivalence determination to Ketalar. Manufacturing initiated with a scalable blow-fill seal process, capable of producing 1 million units per week. Positioned to address U.S. ketamine shortage with preservative-free ketamine.
NRX-100: FDA confirmed willingness to review existing clinical trial data and real-world evidence for approval. NDA filing expected in Q2 2026, targeting broader depression indication.
NRX-101: FDA cleared MIND1 trial for NRX-101 as adjunct to TMS therapy. Trial to enroll 400 participants with potential $1 billion market opportunity. Extended-release form of D-cycloserine validated.
Ketamine Market: U.S. ketamine market exceeds $750 million annually, with additional demand from compounding pharmacies. SPRAVATO generates $2 billion annually, highlighting market potential.
HOPE Therapeutics: Expanded clinic network with 5 operational sites and plans for 8+ by Q2 2026. Partnership with EMOBOT Health to deploy AI-driven depression monitoring app.
Financial Performance: Reduced financial statement loss by 74% year-over-year. Raised $7 million post-Q1 2026, with $6.7 million in cash as of March 31, 2026.
Manufacturing Efficiency: Blow-fill seal process for KETAFREE reduces costs by eliminating glass vials and rubber stoppers, enabling scalable production.
Geneuro Acquisition: Acquired Geneuro assets targeting neurological and autoimmune diseases. Portfolio includes patents, cell lines, and data from clinical trials. Focus on non-dilutive funding.
Military and First Responder Focus: MIND1 trial targets depression and PTSD in military and first responders, addressing critical healthcare and readiness priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company is awaiting final FDA review for KETAFREE and NRX-100, with potential delays or additional requirements posing risks to their approval timelines.
Market Supply and Competition: The ketamine market is structurally undersupplied, but competition from compounding pharmacies and established products like SPRAVATO could impact market share.
Manufacturing and Scalability: While the company has initiated commercial manufacturing, scaling production to meet demand and maintaining quality standards could present operational challenges.
Financial Sustainability: Despite raising $7 million and reducing losses, the company remains reliant on cash resources and at-the-market offerings to sustain operations through 2026.
Clinical Trial Risks: The success of the MIND1 trial and other clinical programs depends on securing non-dilutive funding and achieving positive outcomes, which are not guaranteed.
Economic and Regulatory Environment: Changes in federal laws and executive orders supporting psychedelic medicines could influence approval processes, but reliance on these evolving regulations introduces uncertainty.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
KETAFREE Approval and Market Entry: The company anticipates FDA approval for KETAFREE, a preservative-free ketamine product, by summer 2026. The product is positioned to address a significant market shortage of sterile intravenous ketamine, with scalable manufacturing capabilities to produce 1 million units per week. The company aims to capitalize on the growing demand for ketamine as an alternative to opioids in pain management.
NRX-100 NDA Submission: The company plans to submit the NDA for NRX-100 in the second quarter of 2026. The submission will include clinical trial data from over 1,000 patients and real-world evidence from 65,000 patients. The FDA has guided the company to seek a broader indication for depression in patients who may have suicidality, potentially addressing a market of over 10 million Americans.
NRX-101 Clinical Trials and Market Opportunity: The MIND1 trial for NRX-101, targeting suicidal bipolar depression, has received FDA clearance and is expected to enroll 400 participants. The trial is supported by anticipated nondilutive federal funding and aims to address a market opportunity exceeding $1 billion. The company has also developed an extended-release form of D-cycloserine to support TMS augmentation.
HOPE Therapeutics Expansion: The company expects to expand its HOPE Therapeutics clinic network from 5 to 8 or more locations by the end of the second quarter of 2026. The clinics will integrate AI-driven tools for depression monitoring and aim to enhance patient care and revenue generation.
Geneuro Platform Development: The newly acquired Geneuro platform targets neurological and autoimmune diseases, including schizophrenia, multiple sclerosis, and ALS. The company plans to support this platform through nondilutive funding channels, leveraging existing patents and partnerships with institutions like the NIH.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What does the channel look like for KETAFREE distribution, and how much groundwork is involved?
A:KETAFREE distribution involves two channels: the existing hospital channel for ketamine and the clinic market. The hospital channel benefits from U.S. manufacturing and reliability, while the clinic market currently lacks access to wholesalers and relies on compounding pharmacies. The company plans to replace compounded products with FDA-approved GMP products to address this gap.
Q:What is the level of understanding with the FDA regarding the 65,000 real-world ketamine records?
A:The FDA acknowledges the preliminary data looks promising. The company has submitted a statistical analysis plan to agree on tests, patient inclusion/exclusion criteria, and categorization before analyzing the data. They are awaiting FDA's response, expected by the end of the month.
Q:What are the bottlenecks causing the ketamine shortage, and how does the company plan to overcome them?
A:The company is unsure of the exact reasons for the ketamine shortage, which could involve raw materials or manufacturing capacity. However, they have secured a couple of years' worth of ketamine drug ingredients, high-volume assembly lines, and a manufacturing partner to address the shortage. Raw material availability is not an issue for them.
Q:What might the FDA's action be towards preservative-free ketamine if KETAFREE is approved?
A:The regulatory environment is generally pro-safety and anti-preservative. The company cannot predict FDA actions but notes that the Secretary of Health and the acting FDA commissioner have expressed support for removing toxic preservatives. The preservative in ketamine has not been re-evaluated since the 1970s.
Q:How soon after filing the NRX-100 NDA might the company learn about priority review or a voucher?
A:The process generally takes six months. The company already has Fast Track approval for NRX-100, which entitles them to priority review.
Q:What inventory level does the company expect to have for KETAFREE at launch?
A:The company expects to have at least 1 million units in the warehouse at launch, potentially increasing to 1.5 or 2 million units depending on demand.
Q:Does the company expect a quicker review for NRX-100 with Fast Track or CMPV?
A:Priority review under Fast Track is well-established and speeds up the process. The impact of CMPV on further speeding the process or increasing approval likelihood remains uncertain. The company emphasizes the importance of submitting real-world evidence to the FDA.
Q:Will the MIND1 trial for NRX-101 plus TMS be registration-enabling if positive?
A:If the trial shows dramatically positive results (e.g., P<0.01), it could potentially support approval based on one trial, given the priority around treating depression and suicidality. However, the company emphasizes the importance of completing the trial and obtaining data before speculating.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the exact reasons for the ketamine shortage, citing uncertainty about other companies' supply chain issues. They also did not provide a clear timeline for FDA responses or specific impacts of CMPV on the review process.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Chief
Chief Scientist
Defense
Dr
EMOBOT
FDA
Florida
HOPE
Medical
NDA
NRX
NRx
National
PTSD
TMS
approval
cash
change
clinic
depression
development
drug
end
expense
glass
hand
hospital
indication
ketamine
launch
loss
manufacturing
market
month
opioids
order
patient
portfolio
reduction
review
setting
shortage
suicidality
term
trial
use
world evidence
NRXP Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Unknown5-18
The earnings call presents mixed signals. The financial performance shows a significant reduction in net loss, which is positive, but rising operational costs and reliance on cash resources pose concerns. The Q&A section reveals uncertainties in regulatory approval processes and supply chain issues, but the company's strategic initiatives and FDA engagement offer some optimism. Overall, the sentiment is neutral, as positive and negative factors balance each other out.
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary shows strong financial performance with a 25% revenue increase and a shift to net income from a previous loss, indicating improved profitability. Operating expenses decreased, and cash flow improved significantly. Despite risks associated with forward-looking statements, the financial health and strategic initiatives like clinic expansion and drug development are promising. The absence of negative sentiment in the Q&A further supports a positive outlook. Given these factors, the stock price is likely to experience a positive movement over the next two weeks.
Quarterhill Inc. (QTRH:CA) Q4 2025 Earnings Call Transcript
Positive3-23
The earnings call highlights improving margins, positive adjusted EBITDA, and a successful multiyear transformation, all indicating a stronger operational foundation. The strategic outlook for 2026 is optimistic with growing demand for technology solutions. Despite acknowledging risks and the non-standardized nature of adjusted EBITDA, the overall sentiment is positive. The lack of shareholder return discussion is a minor negative, but not enough to outweigh the positives. Hence, a positive stock price movement of 2% to 8% is expected over the next two weeks.
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript
Unknown11-17
The company's financial performance shows increased losses and limited revenue, but it has a stronger cash position. The strategic plan highlights promising drug developments and market opportunities, yet faces significant market, operational, and scientific risks. The Q&A session reveals some optimism about regulatory paths but also uncertainty and vague responses. Overall, the mixed signals suggest a neutral sentiment, with potential for both positive and negative developments.
NRXP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
